Calkins Daniel sold $21K of VSTM
Calkins Daniel (Chief Financial Officer) sold 2,566 shares of Verastem, Inc. (VSTM) at $8.00 on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
First public disclosure of a CFO's share sale, providing fresh data for short‑term traders.
Market read
New insider sale information may prompt modest short‑term price adjustment.
What to watch
The CFO may be diversifying holdings; the sale size is negligible relative to float.
Background
Form 4 filing discloses insider transactions required by the SEC.
Ticker impact
CFO Daniel Calkins sold 2,566 shares of Verastem for $20,528 via a 10b5‑1 plan, reducing his stake to 123,781 shares.
potential slight downside as the market prices in the CFO's sale
The transaction size is small relative to market cap, but CFO sales are watched by traders and can trigger short‑term selling pressure.
Market effects
Minimal impact on the biotech sector; insider sales are company‑specific.
No broader regional effect.
Limited to investors tracking Verastem.
Counterpoint
The sale could be routine under a pre‑arranged plan and not reflect negative sentiment.
Key entities
- CompanyVerastem, Inc.
Biopharmaceutical company developing cancer therapies.
- IndividualDaniel Calkins
Chief Financial Officer of Verastem.
